PMC:7103735 / 41205-41775 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T379","span":{"begin":39,"end":47},"obj":"Disease"},{"id":"T380","span":{"begin":39,"end":43},"obj":"Disease"},{"id":"T381","span":{"begin":173,"end":181},"obj":"Disease"},{"id":"T382","span":{"begin":173,"end":177},"obj":"Disease"},{"id":"T383","span":{"begin":228,"end":236},"obj":"Disease"},{"id":"T384","span":{"begin":228,"end":232},"obj":"Disease"},{"id":"T385","span":{"begin":341,"end":349},"obj":"Disease"},{"id":"T386","span":{"begin":341,"end":345},"obj":"Disease"},{"id":"T387","span":{"begin":426,"end":434},"obj":"Disease"},{"id":"T388","span":{"begin":426,"end":430},"obj":"Disease"},{"id":"T389","span":{"begin":457,"end":465},"obj":"Disease"},{"id":"T390","span":{"begin":457,"end":461},"obj":"Disease"}],"attributes":[{"id":"A379","pred":"mondo_id","subj":"T379","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A380","pred":"mondo_id","subj":"T380","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A381","pred":"mondo_id","subj":"T381","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A382","pred":"mondo_id","subj":"T382","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A383","pred":"mondo_id","subj":"T383","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A384","pred":"mondo_id","subj":"T384","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A385","pred":"mondo_id","subj":"T385","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A386","pred":"mondo_id","subj":"T386","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A387","pred":"mondo_id","subj":"T387","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A388","pred":"mondo_id","subj":"T388","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A389","pred":"mondo_id","subj":"T389","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A390","pred":"mondo_id","subj":"T390","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Although the exact mechanisms by which SARS-CoV-2 might counteract host antiviral defence remain to be elucidated, this emerging virus is thought to be less pathogenic than SARS-CoV. Our prediction is that the IFN antagonism of SARS-CoV-2 and its ability to suppress other pathways of innate antiviral signalling might fall between those of SARS-CoV and the community-acquired HCoVs. Plausibly, the weakened IFN antagonism of SARS-CoV-2 compared to that of SARS-CoV might lead to more robust host antiviral defence, attenuated viral replication, and lower pathogenicity."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T463","span":{"begin":129,"end":134},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T464","span":{"begin":302,"end":312},"obj":"http://purl.obolibrary.org/obo/SO_0000418"}],"text":"Although the exact mechanisms by which SARS-CoV-2 might counteract host antiviral defence remain to be elucidated, this emerging virus is thought to be less pathogenic than SARS-CoV. Our prediction is that the IFN antagonism of SARS-CoV-2 and its ability to suppress other pathways of innate antiviral signalling might fall between those of SARS-CoV and the community-acquired HCoVs. Plausibly, the weakened IFN antagonism of SARS-CoV-2 compared to that of SARS-CoV might lead to more robust host antiviral defence, attenuated viral replication, and lower pathogenicity."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T142","span":{"begin":72,"end":81},"obj":"Chemical"},{"id":"T143","span":{"begin":292,"end":301},"obj":"Chemical"},{"id":"T144","span":{"begin":497,"end":506},"obj":"Chemical"}],"attributes":[{"id":"A142","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A143","pred":"chebi_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A144","pred":"chebi_id","subj":"T144","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"Although the exact mechanisms by which SARS-CoV-2 might counteract host antiviral defence remain to be elucidated, this emerging virus is thought to be less pathogenic than SARS-CoV. Our prediction is that the IFN antagonism of SARS-CoV-2 and its ability to suppress other pathways of innate antiviral signalling might fall between those of SARS-CoV and the community-acquired HCoVs. Plausibly, the weakened IFN antagonism of SARS-CoV-2 compared to that of SARS-CoV might lead to more robust host antiviral defence, attenuated viral replication, and lower pathogenicity."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T69","span":{"begin":302,"end":312},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T70","span":{"begin":527,"end":544},"obj":"http://purl.obolibrary.org/obo/GO_0019079"},{"id":"T71","span":{"begin":527,"end":544},"obj":"http://purl.obolibrary.org/obo/GO_0019058"}],"text":"Although the exact mechanisms by which SARS-CoV-2 might counteract host antiviral defence remain to be elucidated, this emerging virus is thought to be less pathogenic than SARS-CoV. Our prediction is that the IFN antagonism of SARS-CoV-2 and its ability to suppress other pathways of innate antiviral signalling might fall between those of SARS-CoV and the community-acquired HCoVs. Plausibly, the weakened IFN antagonism of SARS-CoV-2 compared to that of SARS-CoV might lead to more robust host antiviral defence, attenuated viral replication, and lower pathogenicity."}

{"project":"LitCovid-sentences","denotations":[{"id":"T342","span":{"begin":0,"end":182},"obj":"Sentence"},{"id":"T343","span":{"begin":183,"end":383},"obj":"Sentence"},{"id":"T344","span":{"begin":384,"end":570},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Although the exact mechanisms by which SARS-CoV-2 might counteract host antiviral defence remain to be elucidated, this emerging virus is thought to be less pathogenic than SARS-CoV. Our prediction is that the IFN antagonism of SARS-CoV-2 and its ability to suppress other pathways of innate antiviral signalling might fall between those of SARS-CoV and the community-acquired HCoVs. Plausibly, the weakened IFN antagonism of SARS-CoV-2 compared to that of SARS-CoV might lead to more robust host antiviral defence, attenuated viral replication, and lower pathogenicity."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1184","span":{"begin":210,"end":213},"obj":"Gene"},{"id":"1185","span":{"begin":408,"end":411},"obj":"Gene"},{"id":"1186","span":{"begin":39,"end":49},"obj":"Species"},{"id":"1187","span":{"begin":173,"end":181},"obj":"Species"},{"id":"1188","span":{"begin":228,"end":238},"obj":"Species"},{"id":"1189","span":{"begin":341,"end":349},"obj":"Species"},{"id":"1190","span":{"begin":426,"end":436},"obj":"Species"},{"id":"1191","span":{"begin":457,"end":465},"obj":"Species"}],"attributes":[{"id":"A1184","pred":"tao:has_database_id","subj":"1184","obj":"Gene:3439"},{"id":"A1185","pred":"tao:has_database_id","subj":"1185","obj":"Gene:3439"},{"id":"A1186","pred":"tao:has_database_id","subj":"1186","obj":"Tax:2697049"},{"id":"A1187","pred":"tao:has_database_id","subj":"1187","obj":"Tax:694009"},{"id":"A1188","pred":"tao:has_database_id","subj":"1188","obj":"Tax:2697049"},{"id":"A1189","pred":"tao:has_database_id","subj":"1189","obj":"Tax:694009"},{"id":"A1190","pred":"tao:has_database_id","subj":"1190","obj":"Tax:2697049"},{"id":"A1191","pred":"tao:has_database_id","subj":"1191","obj":"Tax:694009"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Although the exact mechanisms by which SARS-CoV-2 might counteract host antiviral defence remain to be elucidated, this emerging virus is thought to be less pathogenic than SARS-CoV. Our prediction is that the IFN antagonism of SARS-CoV-2 and its ability to suppress other pathways of innate antiviral signalling might fall between those of SARS-CoV and the community-acquired HCoVs. Plausibly, the weakened IFN antagonism of SARS-CoV-2 compared to that of SARS-CoV might lead to more robust host antiviral defence, attenuated viral replication, and lower pathogenicity."}